Literature DB >> 25422486

Dilemmas in treating smoldering multiple myeloma.

Inhye E Ahn1, Sham Mailankody1, Neha Korde1, Ola Landgren2.   

Abstract

Novel therapies hold promise for high-risk smoldering multiple myeloma (SMM). Recent studies suggest that modern combination approaches can be options for high-risk SMM to obtain deep molecular responses with favorable toxicity profiles. Although pioneering treatment trials based on small numbers of patients suggest progression-free and overall survival benefits, application of the data to real-life practice remains to be validated. Therapeutic modulation of disease tempo, disease burden, clonal evolution, and tumor microenvironment in SMM remains to be understood and calls for reliable biomarkers reflective of disease biology. Here, we review studies that open a new management platform for SMM, address ongoing dilemmas in practice and under investigation, and highlight emerging scientific questions in the era of SMM treatment.
© 2014 by American Society of Clinical Oncology.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25422486      PMCID： PMC4268248          DOI： 10.1200/JCO.2014.56.4351

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


  74 in total

1.  Treatment for high-risk smoldering myeloma.

Authors:  Sigurdur Y Kristinsson; Erik Holmberg; Cecilie Blimark
Journal:  N Engl J Med       Date:  2013-10-31       Impact factor: 91.245

2.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; Eduardo Olavarría; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

3.  Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.

Authors:  Laurence Lodé; Marion Eveillard; Valérie Trichet; Thierry Soussi; Soraya Wuillème; Steven Richebourg; Florence Magrangeas; Norbert Ifrah; Loïc Campion; Catherine Traullé; François Guilhot; Denis Caillot; Gérald Marit; Claire Mathiot; Thierry Facon; Michel Attal; Jean-Luc Harousseau; Philippe Moreau; Stéphane Minvielle; Hervé Avet-Loiseau
Journal:  Haematologica       Date:  2010-07-15       Impact factor: 9.941

4.  Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.

Authors:  Benjamin M Cherry; Neha Korde; Mary Kwok; Elisabet E Manasanch; Manisha Bhutani; Marcia Mulquin; Diamond Zuchlinski; Mary Ann Yancey; Irina Maric; Katherine R Calvo; Raul Braylan; Maryalice Stetler-Stevenson; Constance Yuan; Prashant Tembhare; Adriana Zingone; Rene Costello; Mark J Roschewski; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2013-07-29

5.  Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.

Authors:  Martin F Kaiser; David C Johnson; Ping Wu; Brian A Walker; Annamaria Brioli; Fabio Mirabella; Christopher P Wardell; Lorenzo Melchor; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2013-05-22       Impact factor: 22.113

6.  Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

Authors:  Madhav V Dhodapkar; Rachael Sexton; Sarah Waheed; Saad Usmani; Xenofon Papanikolaou; Bijay Nair; Nathan Petty; John D Shaughnessy; Antje Hoering; John Crowley; Robert Z Orlowski; Bart Barlogie
Journal:  Blood       Date:  2013-10-21       Impact factor: 22.113

7.  Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.

Authors:  Kai Neben; Anna Jauch; Thomas Hielscher; Jens Hillengass; Nicola Lehners; Anja Seckinger; Martin Granzow; Marc S Raab; Anthony D Ho; Hartmut Goldschmidt; Dirk Hose
Journal:  J Clin Oncol       Date:  2013-10-21       Impact factor: 44.544

8.  Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.

Authors:  S V Rajkumar; V Gupta; R Fonseca; A Dispenzieri; W I Gonsalves; D Larson; R P Ketterling; J A Lust; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2013-03-21       Impact factor: 11.528

9.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Authors:  Jens G Lohr; Petar Stojanov; Scott L Carter; Peter Cruz-Gordillo; Michael S Lawrence; Daniel Auclair; Carrie Sougnez; Birgit Knoechel; Joshua Gould; Gordon Saksena; Kristian Cibulskis; Aaron McKenna; Michael A Chapman; Ravid Straussman; Joan Levy; Louise M Perkins; Jonathan J Keats; Steven E Schumacher; Mara Rosenberg; Gad Getz; Todd R Golub
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

10.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Authors:  Niccolo Bolli; Hervé Avet-Loiseau; David C Wedge; Peter Van Loo; Ludmil B Alexandrov; Inigo Martincorena; Kevin J Dawson; Francesco Iorio; Serena Nik-Zainal; Graham R Bignell; Jonathan W Hinton; Yilong Li; Jose M C Tubio; Stuart McLaren; Sarah O' Meara; Adam P Butler; Jon W Teague; Laura Mudie; Elizabeth Anderson; Naim Rashid; Yu-Tzu Tai; Masood A Shammas; Adam S Sperling; Mariateresa Fulciniti; Paul G Richardson; Giovanni Parmigiani; Florence Magrangeas; Stephane Minvielle; Philippe Moreau; Michel Attal; Thierry Facon; P Andrew Futreal; Kenneth C Anderson; Peter J Campbell; Nikhil C Munshi
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919
View more
  9 in total

Review 1.  New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.

Authors:  Ola Landgren; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

Review 2.  Minimal residual disease in multiple myeloma: bringing the bench to the bedside.

Authors:  Sham Mailankody; Neha Korde; Alexander M Lesokhin; Nikoletta Lendvai; Hani Hassoun; Maryalice Stetler-Stevenson; Ola Landgren
Journal:  Nat Rev Clin Oncol       Date:  2015-01-27       Impact factor: 66.675

Review 3.  Shall we treat smoldering multiple myeloma in the near future?

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.

Authors:  E Zamagni; C Nanni; F Gay; A Pezzi; F Patriarca; M Bellò; I Rambaldi; P Tacchetti; J Hillengass; B Gamberi; L Pantani; V Magarotto; A Versari; M Offidani; B Zannetti; F Carobolante; M Balma; P Musto; M Rensi; K Mancuso; A Dimitrakopoulou-Strauss; S Chauviè; S Rocchi; N Fard; G Marzocchi; G Storto; P Ghedini; A Palumbo; S Fanti; M Cavo
Journal:  Leukemia       Date:  2015-10-22       Impact factor: 11.528

5.  The road to cure in multiple myeloma starts with smoldering disease.

Authors:  Karma Z Salem; Irene M Ghobrial
Journal:  Expert Opin Orphan Drugs       Date:  2015-04-12       Impact factor: 0.694

Review 6.  Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

Authors:  Niels W C J van de Donk; Maarten L Janmaat; Tuna Mutis; Jeroen J Lammerts van Bueren; Tahamtan Ahmadi; A Kate Sasser; Henk M Lokhorst; Paul W H I Parren
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 12.988

7.  Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.

Authors:  O Landgren; S Devlin; M Boulad; S Mailankody
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

Review 8.  What Is New in the Treatment of Smoldering Multiple Myeloma?

Authors:  Niccolo' Bolli; Nicola Sgherza; Paola Curci; Rita Rizzi; Vanda Strafella; Mario Delia; Vito Pier Gagliardi; Antonino Neri; Luca Baldini; Francesco Albano; Pellegrino Musto
Journal:  J Clin Med       Date:  2021-01-22       Impact factor: 4.241

Review 9.  2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.

Authors:  Pellegrino Musto; Monika Engelhardt; Jo Caers; Niccolo' Bolli; Martin Kaiser; Niels Van de Donk; Evangelos Terpos; Annemiek Broijl; Carlos Fernández De Larrea; Francesca Gay; Hartmut Goldschmidt; Roman Hajek; Annette Juul Vangsted; Elena Zamagni; Sonja Zweegman; Michele Cavo; Meletios Dimopoulos; Hermann Einsele; Heinz Ludwig; Giovanni Barosi; Mario Boccadoro; Maria-Victoria Mateos; Pieter Sonneveld; Jesus San Miguel
Journal:  Haematologica       Date:  2021-11-01       Impact factor: 9.941
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.